Not all discoveries are planned. Many a times results of research amaze the researcher itself. A similar instance was noticed when research was being undertaken on Acomplia for its weight loss properties. It was observed that the drug was helpful in reducing cravings for not only food but also smoking. This was a breakthrough discovery and was hailed by people all over the world. Obesity and smoking are two of the most severe problems grappling the society today. Today obesity causes the most number of deaths worldwide, mainly in the form of cardio-vascular complications. Smoking too contributes to nearly 20% of all deaths. A single pill to deal with both these problems - people are swooning over Acomplia's weight loss and anti-smoking properties.
Acomplia is the brand name of Rimonabant . Developed by Sanofi-Aventis, rimonabant works by blocking a pleasure centre. This pleasure centre would get titillated and thus patients would feel hunger pangs. Researchers at Sanofi-Aventis thought that if this pleasure centre were blocked, it would reduce cravings for food. When appetite is dampened, the patient will automatically lose weight.
The idea for developing the pill came from the observations in people who smoked cannabis. After a joint of cannabis, the smokers experienced extreme hunger pangs. Studying the cause of this led them to the body's Endocannabinoid system. Cannabinoid type I or CB1 receptors cause the hunger pangs. Thus, the idea of blocking the CB1 receptors arose.
While the effectiveness of Acomplia has been fully ascertained on the weight loss front, research is still being undertaken on its anti smoking properties.
On the weight loss front, the results of Acomplia have been impressive. Lancet, a medical journal of the UK published the results of a clinical trial conducted in 2005. It was reported in the article that overweight people, who underwent trials lost weight significantly, with just five mgs of rimonabant or Acomplia. With 20 mgs of the drug, the weight loss was 10% or greater than those taking the placebo.
Moreover, Acomplia has been found helpful in reducing waist measurements by doing away with the fat over the problem areas. Some of the other benefits of the drug are increasing insulin resistance and high density lipoprotein cholesterol.
Acomplia has been approved for sale in the UK. It still awaits approval by FDA in the US. Sanofi-Aventis is planning to launch rimonabant by the name of Zimulti rather than Acomplia.
The patient must have been prescribed Acomplia by a certified doctor for purchasing the drug. The drug is available with several internet pharmacies. It is convenient to buy the drug from an online drug store. Moreover, buying Acomplia online helps maintain anonymity of patient. But beware of the fakes that are being sold over the internet. Always buy from a recognized pharmacy to get genuine Acomplia for weight loss and cessation of smoking.
